106 related articles for article (PubMed ID: 38728605)
1. Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease.
Burton C; Allen P; Herrera AF
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433502. PubMed ID: 38728605
[TBL] [Abstract][Full Text] [Related]
2. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
[TBL] [Abstract][Full Text] [Related]
3. Current salvage therapies in Hodgkin lymphoma.
Chohan K; Ansell SM
Leuk Lymphoma; 2022 Jun; 63(6):1267-1280. PubMed ID: 35037568
[TBL] [Abstract][Full Text] [Related]
4. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
5. Novel Therapies in the Treatment of Hodgkin Lymphoma.
Andrade-Gonzalez X; Ansell SM
Curr Treat Options Oncol; 2021 Mar; 22(5):42. PubMed ID: 33755826
[TBL] [Abstract][Full Text] [Related]
6. Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy.
Moskowitz AJ; Herrera AF; Beaven AW
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():477-486. PubMed ID: 31099645
[TBL] [Abstract][Full Text] [Related]
7. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
Othman T; Herrera A; Mei M
Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966
[TBL] [Abstract][Full Text] [Related]
8. [Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma].
Maruyama D
Rinsho Ketsueki; 2020; 61(8):890-900. PubMed ID: 32908053
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
Desai SH; Spinner MA; David K; Bachanova V; Goyal G; Kahl B; Dorritie K; Azzi J; Kenkre VP; Arai S; Chang C; Fusco B; Sumransub N; Hatic H; Saba R; Ibrahim U; Harris EI; Shah H; Murphy J; Ansell S; Jagadish D; Orellana-Noia V; Diefenbach C; Iyenger S; Rappazzo KC; Mishra R; Choi Y; Nowakowski GS; Advani RH; Micallef IN
Am J Hematol; 2023 Mar; 98(3):464-471. PubMed ID: 36629030
[TBL] [Abstract][Full Text] [Related]
10. Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?
Khan N; Moskowitz AJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):227-233. PubMed ID: 28488185
[TBL] [Abstract][Full Text] [Related]
11. Incorporating novel agents into frontline treatment of Hodgkin lymphoma.
Kambhampati S; Herrera AF
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):706-716. PubMed ID: 36485085
[TBL] [Abstract][Full Text] [Related]
12. Sequencing novel agents in the treatment of classical Hodgkin lymphoma.
Ferhanoglu B; Ozbalak M
Expert Rev Hematol; 2023; 16(12):991-1015. PubMed ID: 37897182
[TBL] [Abstract][Full Text] [Related]
13. A review of pathobiology and therapies for classic Hodgkin lymphoma.
Khan M; Hagemeister F; Wang M; Ahmed S
Blood Rev; 2022 Sep; 55():100949. PubMed ID: 35396126
[TBL] [Abstract][Full Text] [Related]
14. [Reaserch Advance on Treatment Strategies for Relapsed/Refractory Hodgkin's Lymphoma--Review].
Jin DC; Zhao L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):343-349. PubMed ID: 32027301
[TBL] [Abstract][Full Text] [Related]
15. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
Martino M; Festuccia M; Fedele R; Console G; Cimminiello M; Gavarotti P; Bruno B
Expert Opin Biol Ther; 2016; 16(3):347-64. PubMed ID: 26652934
[TBL] [Abstract][Full Text] [Related]
16. Programmed Cell Death-One Inhibition Therapy in Classical Hodgkin Lymphoma.
Al-Hadidi SA; Chuang HH; Miranda RN; Lee HJ
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e105-e111. PubMed ID: 33160934
[TBL] [Abstract][Full Text] [Related]
17. Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma.
Choi Y; Diefenbach CS
Curr Oncol Rep; 2020 Jan; 22(1):6. PubMed ID: 31981025
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.
Nikolaenko L; Nademanee A
Future Oncol; 2020 Oct; 16(29):2273-2282. PubMed ID: 32677451
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab for the treatment of Hodgkin Lymphoma.
Al Hadidi SA; Lee HJ
Expert Opin Biol Ther; 2020 Nov; 20(11):1275-1282. PubMed ID: 33006479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]